Shots:
- Repare Therapeutics has entered into a definitive asset purchase agreement with Gilead Sciences for the acquisition of Repare’s RP-3467, a polymerase theta (Polθ) ATPase inhibitor, strengthening Gilead’s precision oncology pipeline
- Under the Agreement, Repare will receive up to $30M in total consideration, including $25M upfront (subject to customary adjustments) and an additional $5M upon completion of specified technology transfer activities
- RP-3467 is a small-molecule Polθ inhibitor being evaluated in the P-I (POLAR) study, both as monotx. and in combination with olaparib, across multiple solid tumors including ovarian, breast, prostate, and pancreatic cancers
Ref: Repare Therapeutics | Image: Repare and Gilead | Press Release
Related News: Health Hope Pharma Collaborates with Gilead Sciences to Advance Encequidar in Virology
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
